Comparison of 18F-FDG and 68-PSMA-11 in PET for prostate cancer diagnosis
DOI:
https://doi.org/10.15392/2319-0612.2022.2007Keywords:
prostate cancer, diagnosis, Positron Emission Tomography ,18F-FDG, 68Ga-PSMA-11.Abstract
Prostate cancer is the second most incident neoplasm in men, except for non-melanoma skin cancer, and has the second highest mortality rate in Brazil. Early diagnosis increases the chances of cure and enables a less aggressive treatment for the patient. Nuclear Medicine presents effective alternatives for prostate cancer diagnosis, such as Positron Emission Tomography (PET) or PET and Computed Tomography (PET/CT) imaging. The aim of this study is to compare the advantages and disadvantages of the radiopharmaceuticals 18F-FDG and 68Ga-PSMA-11 used for PET or PET/CT in the diagnosis of this type of cancer. Compared to 18F-FDG, 68Ga-PSMA-11 has some advantages such as its availability by means of generators, the independent production of a cyclotron facility and its theranostic potential. The disadvantages compared to 18F-FDG are the scalability of 18F-FDG production compared to limited generator production. Despite its favorable characteristics, the radiopharmaceutical 18F-FDG has limitations in the diagnosis of some types of tumors, such as prostate cancer. All the favorable and unfavorable aspects of these two radiopharmaceuticals are presented in this work.
Downloads
References
CAO, Wei et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Medical Journal, v. 134, n. 7, p. 783, 2021. DOI: https://doi.org/10.1097/CM9.0000000000001474
SARACCI, R.; WILD, C. P. International Agency for Research on Cancer - The First 50. Lyon: IARC, 2015. Available at:<http://www.iarc.fr/en/publications/books/iarc50/IARC_50%20years.p
df >. Last accessed: 16 jul. 2021.
SUNG, Hyuna et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, v.71, n. 3, p. 209-249, 2021. DOI: https://doi.org/10.3322/caac.21660
SIEGEL, REBECCA L. et al. Cancer Statistics, 2021. CA: a Cancer Journal for Clinicians, v. 71, n. 1, p. 7-33, 2021. DOI: https://doi.org/10.3322/caac.21654
INSTITUTO NACIONAL DE CÂNCER, 2020. Estimativa 2020. Available at <https://www.inca.gov.br/estimativa/introducao>. Last accessed: 25 mar. 2021.
MINISTÉRIO DA SAÚDE. Secretaria de atenção à saúde. Departamento de ações programáticas estratégicas. Área técnica de saúde do homem. Política nacional de atenção integral à saúde do homem: princípios e diretrizes. Brasília: Ministério da Saúde, 92 p; 2009.
PESQUISA DO INSTITUTO ONCOGUIA. Conhecendo a realidade dos pacientes com câncer de próstata, 2015.
KESCH C, KRATOCHWIL C, MIER W, KOPKA K, GIESEL FL. 68Ga or 18F for prostate cancer imaging? Journal of Nuclear Medicine, v. 58, n. 5, p. 687-688, 2017. DOI: https://doi.org/10.2967/jnumed.117.190157
ALMUHAIDEB, Ahmad; PAPATHANASIOU, Nikolaos; BOMANJI, Jamshed. 18F-FDG PET/CT imaging in oncology. Annals of Saudi medicine, v. 31, n. 1, p. 3-13, 2011. DOI: https://doi.org/10.4103/0256-4947.75771
RUDROFF, Thorsten; KINDRED, John H.; KALLIOKOSKI, Kari K. [18F]-FDG positron emission tomography—an established clinical tool opening a new window into exercise physiology. Journal of Applied Physiology, v. 118, n. 10, p. 1181-1190, 2015. DOI: https://doi.org/10.1152/japplphysiol.01070.2014
MORRIS, Michael J. et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology, v. 59, n. 6, p. 913-918, 2002. DOI: https://doi.org/10.1016/S0090-4295(02)01509-1
SANZ, G. et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU international, v. 84, n. 9, p. 1028-1031, 1999. DOI: https://doi.org/10.1046/j.1464-410x.1999.00349.x
SUNG, J. et al. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU international, v. 92, n. 1, p. 24-27, 2003. DOI: https://doi.org/10.1046/j.1464-410X.2003.04297.x
HILLNER, Bruce E. et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. Journal of Nuclear Medicine, v. 49, n. 12, p. 1928-1935, 2008. DOI: https://doi.org/10.2967/jnumed.108.056713
JACOBSON, Orit; KIESEWETTER, Dale O.; CHEN, Xiaoyuan. Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjugate chemistry, v. 26, n. 1, p. 1-18, 2015. DOI: https://doi.org/10.1021/bc500475e
CALAIS, Jeremie et al. Impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. Journal of Nuclear Medicine, v. 59, n. 3, p. 434-441, 2018.
SONNI, Ida et al. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings : a prospective single-center study. Journal of Nuclear Medicine, v. 61, n. 8, p. 1153-1160, 2020. DOI: https://doi.org/10.2967/jnumed.119.237602
ALBISINNI, Simone et al. Clinical impact of 68Ga‐prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate‐specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU international, v. 120, n. 2, p. 197-203, 2017. DOI: https://doi.org/10.1111/bju.13739
KUTEN, Jonathan et al. Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. Journal of Nuclear Medicine, v. 61, n. 4, p. 527-532, 2020. DOI: https://doi.org/10.2967/jnumed.119.234187
RAUSCHER, Isabel et al. 68 Ga-PSMA ligand PET/CT in patients with prostate cancer : How we review and report. Cancer Imaging, v. 16, n. 1, p. 1- 10, 2016 DOI: https://doi.org/10.1186/s40644-016-0072-6
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
How to Cite
